INTERCEPT PHARMACEUTICALS INC 4
4 · INTERCEPT PHARMACEUTICALS INC · Filed Jun 10, 2015
Insider Transaction Report
Form 4
Adorini Luciano
Chief Scientific Officer
Transactions
- Sale
Common Stock
2015-06-08$250.34/sh−2,000$500,670→ 10,060 total - Sale
Common Stock
2015-06-08$246.46/sh−2,000$492,928→ 12,060 total - Exercise/Conversion
Option to Purchase Common Stock
2015-06-08−4,000→ 67 totalExercise: $8.67Exp: 2021-10-13→ Common Stock (4,000 underlying) - Exercise/Conversion
Common Stock
2015-06-08$8.67/sh+4,000$34,667→ 14,060 total
Footnotes (4)
- [F1]The reported transaction was made pursuant to a 10(b)5-1 plan adopted by the reporting person on March 9, 2015.
- [F2]All the shares underlying this option have fully vested.
- [F3]This transaction was executed in multiple trades at prices ranging from $245.7200 to $246.5700. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This transaction was executed in multiple trades at prices ranging from $250.2400 to $250.4300. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.